“martin-shkreli” Archives

in
Entry Author Date Location
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More 03/06/20 National
Drug Pricing: Innovation, Investment, and the Public Good 09/24/19 Boston
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co-Invented Fails 08/22/19 San Diego
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More 03/15/19 National
Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More 03/08/19 National
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More 01/04/19 National
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More 07/20/18 National
“Pharma Bro” Martin Shkreli Gets Seven Years for Securities Fraud 03/09/18 New York
Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More 03/02/18 National
Bio Roundup: Phase 3 Fails, Shkreli Jailed, Moderna Flip-Flops & More 09/15/17 National
Report: Martin Shkreli Faces Prison Term After Fraud Conviction 08/04/17 New York
Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More 06/30/17 National
Bio Roundup: Big Apple Mo’, Checkpoint Yes and No, CAR-T Death & More 05/12/17 National
New Blood: Biotech CEOs Bring Fresh Experience to Houston Ecosystem 04/03/17 Texas
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More 12/23/16 National
Californians Still Hate Trump, But More Uncertain About Drug Companies 11/03/16 National
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Retrophin Drug Licensed by Shkreli Shows Positive Phase 2 Results 09/07/16 San Diego
Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More 08/26/16 National
Biotech Roundup: Fighting Addiction, Obama Precision, Juno Deaths & More 07/08/16 National
KaloBios Deals With Shkreli After Exiting Bankruptcy With New Cash 07/07/16 San Francisco
What’s Ahead for Biotech in 2016: Q&A With BIO Chair Ron Cohen 03/31/16 New York
Biotech’s Recent Headlines, Reimagined In Verse and On Stage 02/16/16 National
West Coast Bio Roundup: Tessier-Lavigne, Twist, Unity, Grail & More 02/05/16 San Francisco
East Coast Bio Roundup: CRISPR, Tessier-Lavigne, Pricing, Spero & More 02/05/16 Boston
Love ‘Em? Hate ‘Em? No Matter. The Drug Industry Gets What It Wants. 01/19/16 National
Pharmabros, Designer Babies, And Other Final Words For 2015 12/24/15 National
Page 1 of 2 next page »